» Articles » PMID: 31552052

Human T Cell Response to Dengue Virus Infection

Overview
Journal Front Immunol
Date 2019 Sep 26
PMID 31552052
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

DENV is a major public health problem worldwide, thus underlining the overall significance of the proposed Program. The four dengue virus (DENV) serotypes (1-4) cause the most common mosquito-borne viral disease of humans, with 3 billion people at risk for infection and up to 100 million cases each year, most often affecting children. The protective role of T cells during viral infection is well-established. Generally, CD8 T cells can control viral infection through several mechanisms, including direct cytotoxicity, and production of pro-inflammatory cytokines such as IFN-γ and TNF-α. Similarly, CD4 T cells are thought to control viral infection through multiple mechanisms, including enhancement of B and CD8 T cell responses, production of inflammatory and anti-viral cytokines, cytotoxicity, and promotion of memory responses. To probe the phenotype of virus-specific T cells, epitopes derived from viral sequences need to be known. Here we discuss the identification of CD4 and CD8 T cell epitopes derived from DENV and how these epitopes have been used by researchers to interrogate the phenotype and function of DENV-specific T cell populations.

Citing Articles

Comprehensive immune profiling of dengue and chikungunya viral responses using a novel miniaturized automated whole blood cellular analysis system and mass cytometry in a pediatric cohort in Msambweni, Kenya.

Kowli S, Krystosik A, Hale M, Mutuku F, Amugongo J, Malumbo S Immunohorizons. 2025; 9(4).

PMID: 40048709 PMC: 11884800. DOI: 10.1093/immhor/vlaf006.


Dengue Virus Infection: Immune Response and Therapeutic Targets.

Tin Ern N, Komarasamy T, Adnan N, Balasubramaniam V Am J Trop Med Hyg. 2024; 112(1):37-44.

PMID: 39531732 PMC: 11720763. DOI: 10.4269/ajtmh.23-0545.


Long term T cell response and safety of a tetravalent dengue vaccine in healthy children.

Mandaric S, Friberg H, Saez-Llorens X, Borja-Tabora C, Biswal S, Escudero I NPJ Vaccines. 2024; 9(1):192.

PMID: 39420169 PMC: 11487277. DOI: 10.1038/s41541-024-00967-0.


TCR repertoire dynamics and their responses underscores dengue severity.

Khare K, Yadav S, Tarai B, Budhiraja S, Pandey R iScience. 2024; 27(10):110983.

PMID: 39403197 PMC: 11472631. DOI: 10.1016/j.isci.2024.110983.


Immunomodulation in dengue: towards deciphering dengue severity markers.

Dash M, Samal S, Rout S, Behera C, Sahu M, Das B Cell Commun Signal. 2024; 22(1):451.

PMID: 39327552 PMC: 11425918. DOI: 10.1186/s12964-024-01779-4.


References
1.
Zivny J, DeFronzo M, Jarry W, Jameson J, Cruz J, Ennis F . Partial agonist effect influences the CTL response to a heterologous dengue virus serotype. J Immunol. 1999; 163(5):2754-60. View

2.
Loke H, Bethell D, Phuong C, Dung M, Schneider J, White N . Strong HLA class I--restricted T cell responses in dengue hemorrhagic fever: a double-edged sword?. J Infect Dis. 2001; 184(11):1369-73. DOI: 10.1086/324320. View

3.
Zivna I, Green S, Vaughn D, Kalayanarooj S, Stephens H, Chandanayingyong D . T cell responses to an HLA-B*07-restricted epitope on the dengue NS3 protein correlate with disease severity. J Immunol. 2002; 168(11):5959-65. DOI: 10.4049/jimmunol.168.11.5959. View

4.
Mongkolsapaya J, Dejnirattisai W, Xu X, Vasanawathana S, Tangthawornchaikul N, Chairunsri A . Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med. 2003; 9(7):921-7. DOI: 10.1038/nm887. View

5.
Gwinn W, Sun W, Innis B, Caudill J, King A . Serotype-specific T(H)1 responses in recipients of two doses of candidate live-attenuated dengue virus vaccines. Am J Trop Med Hyg. 2004; 69(6 Suppl):39-47. DOI: 10.4269/ajtmh.2003.69.39. View